Accelrys software to support efforts in Texas to study rare cancers

Accelrys ($ACCL) has deepened its ties to Texas research institutions. The San Diego-based provider of R&D software has inked a 5-year deal with the Gulf Coast Consortia for Quantitative Biomedical Sciences, which involves researchers from multiple fields and centers in Texas who are teaming up to advance treatment and prevention of diseases such as rare cancers, according to Accelrys.

A key to the agreement involves connecting researchers and data from multiple institutions. Scientists from the consortia--which involves 11 research centers in Texas--will be able to access Accelrys' Pipeline Pilot scientific authoring software, the cloud-based HEOS platform, the modeling and simulation tool known as Discovery Studio and Accelrys Biological Registration software. The HEOS software provides an online workspace for researchers to share and manage data.

"Large inter-institutional cooperatives focused on collaborative research and interdisciplinary training represent a new operating paradigm in academia today," Matt Hahn, Accelrys' senior vice president and chief technology officer, said in a statement. "Accelrys' unifying Enterprise Platform defines a new standard in integrated research informatics for multi-center collaborations."

The members of the consortium include: Baylor College of Medicine, Rice University, University of Houston, University of Texas Health Science Center at Houston, University of Texas MD Anderson Cancer Center, University of Texas Medical Branch at Galveston, The Methodist Hospital Research Institute, The University of Texas at Austin - Texas Institute for Drug and Diagnostic Development, Texas A&M Health Science Center – Institute for Biosciences and Technology, Texas Southern University and The University of Texas-El Paso.

- here's the release